S28463 (R-848), an analog of imiquimod, is a member of the imidazoquinoline family that have been described as immune response modifiers. Numerous members of this family of compounds exhibit potent antiviral (8, 32) , tumoricidal (10, 27, 37) , and adjuvant activities (9, 46 ). An imiquimod cream, Aldara, is currently being administered in humans for the treatment of external genital warts caused by the human papillomavirus (HPV) (11, 19, 41) .
The imidazoquinolines have no inherent antiviral or cytotoxic effect but seem to stimulate the innate and acquired arm of the immune response (3). They were first described as potent inducers of alpha and beta interferons (IFN-␣/␤) in the sera of mice (35) , chickens (28) , and humans (51) that had been orally treated with these compounds. The imidazoquinolines have also been shown to induce the secretion of a whole spectrum of cytokines, such as interleukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor alpha (TNF-␣) in a number of animal models such as the mouse, the guinea pig, and the monkey (26, 29, 35, 42, 51) . Imidazoquinolines can also induce cytokine secretion as well as maturation of dendritic cells, as shown by increased T-cell proliferation in the presence of imiquimodtreated dendritic cells (1, 17) . B-cell maturation and antibody production are also enhanced by these compounds (45) . Furthermore, Langerhans cell migration to the draining lymph node is increased in imiquimod-treated mice (40) .
The exact mechanism by which the imidazoquinolines exert their effect is currently unknown. A number of transcription factors and protein tyrosine kinases have been shown to be important for some but not all of the effects of these compounds. Some of these crucial factors include STAT1 (13) , NF-B, and AP-1 (15) , which are transcription factors controlling the expression of a number of immune response genes. Protein kinase C (31), Jun kinase, and the mitogen-activated protein kinase p38 (45) have all been shown to play a role in the response to the imidazoquinolines, although the exact biochemical pathway used to activate them remains to be elucidated.
The macrophage has been characterized as the main target for the imidazoquinolines (20) , and the cytokines produced in response to these compounds, such as IL-12, are able to skew the immune response toward a T H 1 phenotype (50) . This type of response is crucial against intracellular pathogens such as viruses and intracellular parasites. In accordance with these findings, S28463 has been shown to effectively activate macrophage killing of Leishmania both in vivo and in vitro through inducing the synthesis of nitric oxide (NO) (15) . More recently, through a gene array approach, it was revealed that S28463 induced the expression of numerous genes which are associated with macrophage activation and the inflammatory response (16) . Based on these observations, we hypothesized that S28463 may also be effective against Mycobacterium bovis BCG.
The susceptibility to infection with Leishmania donovani, M. bovis BCG, and Salmonella enterica serovar Typhimurium was shown to be regulated by an autosomal dominant gene located on chromosome 1 in mice (7, 18, 47) . The natural resistance-associated macrophage protein 1 (NRAMP1) encodes a macrophage-restricted transmembrane protein that shows homology with other eukaryotic transporter proteins of the non-ATP-binding cassette type (4, 21) . In mice, two alleles of the Nramp1 gene have been described. The wild-type allele (Nramp1 r ) conferring resistance to infection has a glycine residue at position 169, while the other allele (Nramp1 s ) has an aspartic acid residue at the same position, leading to susceptibility to intracellular pathogens (49) . This aspartic acid substitution was found to be in absolute association with the M. bovis BCG susceptibility phenotype in all tested mouse strains.
Mice (33) . Since NRAMP1 is localized in the late phagosomal/early endosomal vesicle (22) , it could modulate the intravesicular environment and control the proliferation of some intracellular pathogens.
Since imidazoquinolines (S28463 and imiquimod) were shown to be effective against Leishmania spp. (15), and because resistance to this pathogen is controlled at the Nramp1 locus (14) , we hypothesized that imidazoquinolines may affect the Nramp1-dependent macrophage activation during the course of infection with M. bovis BCG or other intracellular pathogens such as L. donovani.
In this study, we demonstrated that expression of the NRAMP1 protein is required for the optimal induction of nitric oxide production in macrophages treated with S28463. Our results also demonstrate that Nramp1 gene expression plays an important role in the regulation of the efficiency of imidazoquinoline-induced macrophage activation in mice as seen by the inability of Nramp1 Ϫ/Ϫ mice to reduce M. bovis BCG proliferation.
MATERIALS AND METHODS
Bacteria and reagent. M. bovis BCG substrain Montreal was cultivated using constant rotation at 37°C for 2 weeks in Middlebrook 7H9 broth supplemented with 10% Middlebrook OADC enrichment (Becton Dickinson, Cockeysville, Md.) and containing 0.05% Tween 80. After the culture reached an optical density at 600 nm of 0.6 to 1.0, cells were collected, briefly sonicated to disrupt bacterial clumps, and filtered through a 5-m syringe filter to eliminate remaining clumps. After estimation of cell concentration, the culture was aliquoted and frozen in 15% glycerol solution. S28463 is a propriety of 3M Pharmaceuticals and was kindly provided by R. Miller (3M Pharmaceuticals). IFN-␥ was purchased from Invitrogen (Burlington, Ontario, Canada).
Mice. B10A mice were purchased from the National Cancer Institute (Frederick, Md.). B10A.Nramp1 r mice, expressing the wild-type allele of the Nramp1 gene, and B10A.Nramp1
Ϫ/Ϫ mice generated from 129/J mice which had the Nramp1 gene disrupted (48) and backcrossed for 16 generations to the B10A.Nramp1 r genetic background were bred according to the animal care committee protocol in the Montreal General Hospital Research Institute Animal Facility under specific-pathogen-free (SPF) condition.
Cells. Macrophage cell lines were derived from the bone marrow of B10A.Nramp1 r mice (B10A.Nramp1 r cell line) and of B10A.Nramp1 Ϫ/Ϫ mice (B10A.Nramp1
Ϫ/Ϫ cell line). Cell lines were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (HyClone, Logan, Utah) and 1% penicillin-streptomycin antibiotic mixture (Invitrogen). Subconfluent cell cultures were used for all experiments.
Quantification of nitrite production by macrophages. Two to four hours prior to stimulation, B10A.Nramp1 r and B10A.Nramp1 Ϫ/Ϫ cell lines were plated at a concentration of 1 million cells/ml. The cells were subsequently treated with IFN-␥ (10 U/ml) and/or S28463 (25 ng/ml) for 24 h. The estimation of NO 2 Ϫ in supernatants of stimulated and nonstimulated macrophages was performed by colorimetric spectrophotometry at 543 nm using the Griess reagent. Background values for the media were subtracted from those obtained for all experimental samples. Results are expressed as the micromolar concentration of nitrite per microgram of protein. Protein concentrations were determined using the BioRad protein assay.
Infection of mice and determination of spleen CFU. B10A.Nramp1 r , B10A.
Nramp1
Ϫ/Ϫ , and F 1 B10A.Nramp1 r ϫ B10A.Nramp1 Ϫ/Ϫ mice were infected intravenously with M. bovis BCG at the dose indicated in the Results section. They were subsequently injected intraperitoneally every 2 days with various doses of S28463 for 2 weeks (see Results). The mice were then sacrificed by CO 2 inhalation. The spleens were removed and homogenized in 4 ml of 0.25% saponin solution using a Polytron. Subsequently, various dilutions of the homogenized samples were plated on Dubos solid agar. Plates were incubated at 37°C for 2 weeks, and the number of CFU was counted to assess the bacterial burden.
Statistical analysis. A Mann and Whitney nonparametric test was performed using the SigmaStat software (SPSS, Chicago, Ill.) to calculate statistical significance. Potential differences among treatments are considered significantly different when the P values are lower than 0.05.
RESULTS

S28463
induces NO production alone in B10A.Nramp1 r and B10A.Nramp1
؊/؊ macrophage cell lines and acts synergistically with IFN-␥. It has previously been shown that imidazoquinolines could induce the secretion of numerous cytokines by various cell types, including macrophages (26, 35, 39, 51) , and it has been observed that Nramp1 s macrophages do not respond efficiently to IFN-␥ treatment, resulting in low levels of NO upon stimulation (5) . To determine whether the presence of the Nramp1 gene was essential for activation of macrophages by S28463 and also to study the possible interplay between imidazoquinolines and IFN-␥, B10A.Nramp1 r and B10A.Nramp1
Ϫ/Ϫ cells were treated for 24 h with S28463 (25 ng/ml) with or without IFN-␥ (10 U/ml) (Fig. 1) . S28463 alone or in combination with IFN-␥ induced a significant increase in NO production (P Ͻ 0.001 in all cases) in B10A. r ϫ B10A.Nramp1 Ϫ/Ϫ mice were infected intravenously with 5 ϫ 10 5 CFU of M. bovis BCG and injected intraperitoneally every 2 days with S28463 (2 g/mouse) for a period of 2 weeks. The spleens were homogenized, plated, and incubated at 37°C, and the CFU were determined 2 weeks later. Treatment with S28463 significantly reduced the amount of CFU present in the spleen of B10A.Nramp1 r from 13,432 to 4,959 CFU per spleen (P Ͻ 0.001, n ϭ 13 for PBS-injected and n ϭ 12 for S28463 treatment) ( Fig. 2A) . Since the B10A.Nramp1 r mice are naturally resistant to M. bovis BCG infection, an infectious dose five times higher than that used with the B10A.Nramp1 Ϫ/Ϫ mice was administered, although similar effects were observed in these mice at an infectious dose of 10 5 CFU of M. bovis BCG (data not shown). F 1 B10A.Nramp1 r ϫ B10A.Nramp1 Ϫ/Ϫ mice also showed a significant reduction in the bacterial load from 10,400 to 5,600 CFU (P Ͻ 0.001, n ϭ 7 for both groups) (Fig. 2B) . These findings show that S28463 is effective against M. bovis BCG infection and that the presence of one functional allele of the Nramp1 gene is sufficient for complete responsiveness to this compound.
S28463 fails to reduce bacterial load in B10A.Nramp1
؊/؊ mice. Nramp1 s and Nramp1 Ϫ/Ϫ mice have previously been shown to display numerous differences in their immunological response compared to wild-type mice. Some of these differences include the production of some crucial cytokines, such as IFN-␥ (43). To determine the role of Nramp1 in the responsiveness to imidazoquinolines in vivo, B10A.Nramp1 Ϫ/Ϫ mice were infected intravenously with 10 5 M. bovis BCG and injected intraperitoneally every 2 days with different doses of S28463 (from 2 to 50 g). After 2 weeks of treatment the animals were sacrificed, and the spleens were collected, homogenized, and plated. The CFU were subsequently counted after 2 weeks. No significant reduction in bacterial load could be observed with the dose of S28463 shown to be effective in B10A.Nramp1 r mice (2 g) or doses 4, 8, or 25 times higher (P Ͼ 0.05 for all the doses tested) (Fig. 3) . These results and those presented in Fig. 2 . Once the mice were sacrificed, the spleen was removed, homogenized, plated at various dilutions, and incubated for 2 weeks. The colonies were then counted, which enabled the determination of the total amount of bacteria. Data are presented as the median from three and two independent experiments for panels A and B, respectively. Differences in CFU between PBS-treated and S28463-treated mice were significant (P Ͻ 0.001) in both panel A and panel B.
spond to a dose of S28463 effective in B10A.Nramp1 r mice (2 g), it is still possible that dramatically higher doses of imidazoquinolines could rescue these mice from their lack of responsiveness. In order to test this hypothesis, B10A.Nramp1 Ϫ/Ϫ mice were infected with 10 5 M. bovis BCG and treated every 2 days with 500 g of S28463, which is 250 times higher than the effective dose used in mice carrying a wild-type allele of Nramp1. After 2 weeks, spleens were collected to measure bacterial load, and the splenic ratio was calculated. Treatment with the high dose of S28463 led to a small but significant decrease in the amount of bacteria found in the spleen from 232,500 to 175,250 CFU (P ϭ 0.034, n ϭ 11 for PBS treatment and n ϭ 12 for S28463 treatment) (Fig. 4A ), albeit to a much lower level than what is observed in B10A.Nramp1 r (data not shown). At this dose (500 g), S28463 induced a twofold increase in the splenic ratio of both B10A.Nramp1 Ϫ/Ϫ (P Ͻ 0.001) (Fig. 4B ) and B10A.Nramp1 r mice (data not shown). Taken together, these results demonstrate that at much higher doses, B10A.Nramp1 Ϫ/Ϫ mice are able to respond to S28463, although less efficiently than in B10A.Nramp1 r mice.
DISCUSSION
The study presented here demonstrates that S28463 alone can induce NO production in B10A.Nramp1 r macrophages and that a synergistic effect is observed when S28463 is combined with IFN-␥ to increase NO secretion. Although it had previously been demonstrated that S28463 alone could induce NO production in bone marrow-derived macrophages (15) , the effect of S28463 in conjunction with IFN-␥ has never been reported.
The response to S28463 in an Nramp1 Ϫ/Ϫ macrophage cell line was also analyzed. It was observed that lower levels of NO were produced in response to IFN-␥, which is in agreement with what has previously been observed in our laboratory (5) . Treatment with S28463 induced production of NO, but to a lesser extent than that observed in B10A.Nramp1 r macrophages. Treatment with IFN-␥ and S28463 induced a significant production of NO from these cells, indicating that S28463 may be bypassing the IFN-␥ signaling pathway and activating downstream effector molecules. These components may include the NF-B transcription factor as well as AP-1 and c-Fos, all of which were shown to be activated by S28463 (15, 45) .
The effect of S28463 on M. bovis BCG infection was also tested in this study. We demonstrated that S28463 is able to reduce the amount of M. bovis BCG present in the spleen of B10A.Nramp1 r and F1 B10A.Nramp1 r ϫ B10A.Nramp1 5 M. bovis BCG and injected intraperitoneally every 2 days with S28463 (500 g/mouse). Once the mice were sacrificed, the spleen was removed, homogenized, plated at various dilutions, and incubated for 2 weeks. The colonies were then counted, which enabled the determination of the total amount of bacteria. Data are presented as the median from three independent experiments. S28463 treatment led to a significant reduction in CFU (P ϭ 0.034). (B) Splenic ratios were calculated from the PBS-and S28463-treated mice by dividing the weight of the spleen by the total body weight of the mouse. Data are presented as the median from three independent experiments. Treatment with 500 g of S28463 led to a significant increase in the splenic ratio of B10A.Nramp1 Ϫ/Ϫ (P Ͻ 0.001).
Since NO was found to be directly toxic to M. bovis BCG, an increase in NO production would result in more efficient destruction of the bacteria. We showed that S28463 was able to reduce the bacterial load in B10A.Nramp1 r mice, but not in B10A.Nramp1 Ϫ/Ϫ mice at a dose of 2 g per injection. A number of factors may explain this discrepancy. First, it was previously shown that Nramp1 s mice produce less IFN-␥ early in infection compared to Nramp1 r mice (43), which could have an effect on NO production by the macrophages. Second, S28463 was shown to induce IL-12 production (50), which triggers CD4 T cells to produce IFN-␥. Susceptible mice may have a defect in the production of IL-12 that would decrease the amount of IFN-␥ present. Another explanation for the difference observed is that the kinetic of M. bovis BCG infection for susceptible mice may be different than for resistant mice. Since Nramp1 Ϫ/Ϫ mice exhibit 100-fold more CFU in their spleens than B10A.Nramp1 r mice, the state of infection, which is controlled by the Nramp1 gene, differs between these two mouse strains, which could interfere with the immunomodulatory function of S28463.
Of note is the observation that treatment of B10A.Nramp1
Ϫ/Ϫ mice with a dose 250 times higher than that used for the B10A.Nramp1 r mice leads only to a small but significant decrease in bacterial load at the end of infection with M. bovis BCG. This clearly demonstrates that the lack of the Nramp1 gene in these mice leads to a defect that cannot be overcome by using a higher dose of imidazoquinolines. Since Nramp1 is expressed almost exclusively in macrophages (21) and since these cells are also the main effectors in the response to imidazoquinolines (20) , any defect in Nramp1 gene expression or function will lead to a severe impairment in the in vivo response to these compounds. It was also observed after exposure to a high dose of S28463 that the splenic ratio increased twofold in both B10A.Nramp1 r and B10A.Nramp1 Ϫ/Ϫ mice. This increase could be due to proliferation of lymphocytes, especially B cells, which were shown to proliferate in response to imidazoquinolines (45) . Although this increase in B cells could be beneficial for certain types of infection, it did not have a major effect on the course of M. bovis BCG infection in B10A.Nramp1 Ϫ/Ϫ mice. Studies have already shown that responsiveness to imidazoquinolines varies from patient to patient and that the interferon response might be involved (2) . Our model allows us to study these differences in an animal model as well to search for the critical pathway used by the imidazoquinolines. The data presented in this study suggest an important role for the Nramp1 gene in controlling the response to imidazoquinolines. This may be of crucial importance in determining the outcome of treatment for patients receiving imidazoquinolines as treatment for warts induced by HPV or for cancer treatment.
